Drug resistance in patients experiencing early virological f... : AIDS Drug resistance in patients
experiencing early virological failure under a triple combination including indinavir : AIDS Log …

Virological suppression rates achieved with the new antiretroviral drugs in patients with
virological failure and resistance to multiple drug classes are nearly matching the rates seen …

Objectives To assess the role of resistance mutations in subjects experiencing virological
failure on zidovudine (ZDV) and lamivudine (3TC) combined with a protease inhibitor (PI) to …

Objective To assess the prevalence of mutations in the reverse-transcriptase (RT) and
protease (PR) region in a cohort of chronically-infected HIV-positive patients requiring highly …

The emergence of drug-resistant human immunodeficiency virus type 1 is a frequent cause
of failure of combination therapies comprising reverse transcriptase and protease inhibitors …

Objective To study the appearance of drug-induced mutations at low viraemia in treated HIV-
1-infected patients. Design and methods Fourteen patients, who received their first (n= 5) …

The objective was to study the persistence of drug resistance mutations detected earlier at
virological failure during second or third line antiretroviral therapy. Therefore, in HIV‐1 …

Objective: To assess the patterns of HIV phenotypic cross-resistance to protease inhibitors
(PI) in patients experiencing viral load rebound on combination therapy including a PI …

The objectives of this study were to determine the genotypic and phenotypic patterns of
resistance in a group of early-stage antiretroviral-naive patients failing initial therapy with …

Virological failure under protease inhibitor (PI)-based antiretroviral regimens is often not
explained by the selection of resistance mutations. The role of low indinavir (IDV) plasma …